Rationelles Screening bei Nebennierentumoren

Abstract

The characterization of adrenal tumors may become difficult for different reasons. Medical imaging is insufficient to establish a diagnosis, clinical symtoms may vary and medication interfers with lab analysis. Furthermore, hormonal measurements gain diagnostic power with endocrine function tests. This article reviews diagnostic and therapeutic strategies in the management of patients with adrenal tumors.

Die Abklärung von Nebennierentumoren ist aus verschiedenen Gründen schwierig und unübersichtlich. Die Bildgebung kann unzureichend sein, die klinische Symptomatik ist vielseitig und Medikamente interferieren mit den Laboranalysen. Zudem gewinnt die Hormonanalytik erst durch Funktionstests eine zuverlässige Aussagekraft. Dieser Artikel soll Aspekte referieren, an denen sich die diagnostischen und therapeutischen Strategien aktuell orientieren.

Schlüsselwörter

Nebennieren - Tumoren - Diagnostik

Key words

adrenal glands - tumors - diagnosis

• Literatur

• 1 Grumbach MM, Biller BM, Braunstein GD. et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003; 138: 424-429
• 2 Mansmann G, Lau J, Balk E. et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25: 309-340
• 3 Kosilek RP, Frohner R, Würtz RP. et al. Diagnostic use of facial image analysis software in endocrine and genetic disorders: review, current results and future perspectives. Eur J Endocrinol 2015; 173: M39-M44
• 4 Carroll TB, Findling JW. The diagnosis of Cushing’s syndrome. Rev Endocr Metab Disord 2010; 11: 147-153 . doi:10.1007/s11154-010-9143-3
• 5 Willenberg HS. How to Escape from Primary Aldosteronism? News and views on an adrenal disorder of salt retention. Horm Metab Res 2017; 49: 151-163 . doi:10.1055/s-0043-100767
• 6 Späth M, Korovkin S, Antke C. et al. Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. Eur J Endocrinol 2011; 164: 447-455 . doi:10.1530/EJE-10-1070
• 7 Arlt W, Lang K, Sitch AJ. et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2017; 2 (08) pii: 93136 . doi:10.1172/jci.insight.93136
• 8 Gruber M, Därr R, Eisenhofer G. Pheochromocytoma: update on diagnosis and therapy. Dtsch Med Wochenschr 2014; 139: 486-490 . doi:10.1055/s-0033-1360082
• 9 Nieman LK, Biller BM, Findling JW. et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540 . doi:10.1210/jc.2008-0125
• 10 Funder JW, Carey RM, Mantero F. et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916 . doi:10.1210/jc.2015-4061
• 11 Lenders JW, Duh QY, Eisenhofer G. et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 1915-1942 . doi:10.1210/jc.2014-1498
• 12 Plouin PF, Amar L, Dekkers OM. et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 2016; 174: G1-G10 . doi:10.1530/EJE-16-0033
• 13 Willenberg HS, Gruber M, Eisenhofer G. et al. Endocrine hypertension: new aspects and developments. Dtsch Med Wochenschr 2012; 137: 627-630 . doi:10.1055/s-0031-1298989
• 14 Fassnacht M, Arlt W, Bancos I. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-G34 . doi:10.1530/EJE-16-0467
• 15 Willenberg HS. Wichtige Aspekte des Nebennierenrindenkarzinoms. Der Onkologe 2016; 6: 431-445
• 16 Blondin D, Quack I, Haase M. et al. Indication and technical aspects of adrenal blood sampling. Rofo 2015; 187: 19-28 . doi:10.1055/s-0034-1385081
• 17 Williams TA, Lenders JWM, Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699 . doi:10.1016/S2213-8587(17)30135-3
• 18 Berruti A, Baudin E, Gelderblom H. et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (07) VII131-VII138